From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma

Jonathan D Licht, Jake Shortt, Ricky W Johnstone

Research output: Contribution to journalEditorialOtherpeer-review

18 Citations (Scopus)

Abstract

Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents bind to cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for MM growth.
Original languageEnglish
Pages (from-to)9 - 11
Number of pages3
JournalCancer Cell
Volume25
Issue number1
DOIs
Publication statusPublished - 2014
Externally publishedYes

Cite this